<DOC>
	<DOC>NCT02985593</DOC>
	<brief_summary>The objectives of this study are to evaluate the safety and tolerability of a single intravenous (IV) or subcutaneous (SC) dose of KHK4083 in Japanese or White healthy men in a placebo-controlled, single-blind comparative study, and to evaluate the safety and tolerability of multiple IV doses of KHK4083 in subjects with ulcerative colitis in an open-label study.</brief_summary>
	<brief_title>A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>"Part1: 1. Voluntary written informed consent to participate in the study; 2. Japanese or White men ≥20 and &lt;45 years at the time of informed consent; 1. Current illness requiring treatment; 2. Current respiratory, gastric, renal, or liver disease; Part2: 1. Voluntary written informed consent to participate in the study; 2. Men or women ≥20 years of age at the time of informed consent; 3. Ulcerative colitis diagnosed ≥6 months prior to informed consent; 4. Moderate or more severe ulcerative colitis; 1. Definitive diagnosis of bacillary dysentery, amebic colitis, Salmonella enteritis, Campylobacter enteritis, colonic tuberculosis, Chlamydia enteritis, Crohn's disease, radiation colitis, druginduced colitis, angiolymphoid hyperplasia, ischemic colitis, or intestinal Behcet's disease; 2. Any of the following clinically significant concurrent illnesses: Type 1 diabetes Poorly controlled type 2 diabetes (HbA1c &gt;8.5%) Congestive heart failure (class II to IV of the New York Heart Association classification) Myocardial infarction within 1 year Unstable angina pectoris within 1 year Poorly controlled hypertension (systolic pressure &gt;150 mmHg or diastolic pressure &gt;90 mmHg at screening) Severe chronic lung diseases requiring oxygen therapy Multiple sclerosis or other demyelinating diseases Active malignancies, or onset or a history of treatment of malignancies within 5 years prior to informed consent (except for resected or surgically cured epithelial carcinoma of the uterine cervix, cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, or ductal carcinoma); 3. Current or past history of clinically significant cardiovascular, liver, renal, respiratory, hematologic, central nervous system, psychiatric, or autoimmune diseases/disorders other than those in 2); 4. Suspected or confirmed symptomatic stenosis of the colon, abdominal abscess, or ischemic colitis based on clinical or radiographic data within 1 year prior to enrollment; suspected or confirmed toxic megacolon or history of toxic megacolon; history of any colonic resection, subtotal or total colectomy, ileostomy, or colostomy; or any previous surgery for ulcerative colitis or an anticipated requirement for surgery for ulcerative colitis; 5. Known colonic dysplasia, adenomas, or polyposis (excluding benign polyposis); 6. Any planned surgical treatment during the study; 7. Clostridium difficile infection within 8 weeks prior to enrollment; 8. Any active infection, including Grade ≥2 localized diseases per Common Terminology Criteria for Adverse Events, version 4.0, Japan Clinical Oncology Group edition (CTCAE v4.0JCOG), within 4 weeks prior to enrollment; 9. Treatment with 5aminosalicylic acid (5ASA) enema, 5ASA suppository, steroid enema, or steroid suppository within 2 weeks prior to enrollment; 10. Treatment with adalimumab within 2 weeks prior to enrollment or treatment with infliximab within 8 weeks prior to enrollment;</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>